药明生物(HK02269)近日宣布,公司将出售旗下爱尔兰疫苗设施相关的资产。该交易成交额预计为5亿美元,接盘方则为美国制药企业默沙东。 药明生物此前发布的新闻稿显示,爱尔兰疫苗基地由公司全资附属公司药明海德投资建设,预计投资2.4亿美元,并与某国际知名药企签订价值30亿美元的长期合作合同。结合此次交易公告,前述合作对象正是默沙东。 针对该交易,药明生物方面对《每日经济新闻》记者表示:“药明生物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.